Peter Attia Almost Worked for Theranos

Episode Summary

Main Topics

This episode primarily details Peter Attia's personal near-miss with Theranos, specifically his experience almost becoming the company's Chief Medical Officer in 2006. It delves into his initial skepticism regarding Elizabeth Holmes's diagnostic technology, the critical "black box" incident, and his ultimate decision to decline the role due to a lack of transparency. The conversation then explores the eventual unraveling of Theranos following John Carreyrou's Wall Street Journal exposé in 2015, contrasting Attia's early suspicions with the widespread deception that ensnared numerous prominent figures and investors. The hosts reflect on the broader lessons about corporate due diligence, the allure of charismatic founders, and the importance of scientific integrity over hype.

Key Discussion Points

• Early Engagement with Theranos: Peter Attia recounts how, in 2006, a friend whose father-in-law was a Stanford professor and board member introduced him to Elizabeth Holmes. At the time, Theranos was a small startup of about 30 people, located near Attia's McKinsey office in Palo Alto. He was considered for the Chief Medical Officer position and had lunch with Holmes, an experience he describes as pivotal in his decision.
• The "Edison Box" and Technical Scrutiny: During his meeting, Attia was shown a "black box," possibly the precursor to the Edison device. Drawing on his two years at the NIH and understanding of chemical assays like ELISA, he questioned how the device could perform complex biomarker measurements, such as insulin levels, from a single drop of blood. He specifically highlighted the necessity of extensive washing and rinsing for such assays, which seemed incompatible with Holmes's claims.
• Refusal to Show Internal Mechanics: Attia requested to see the inside of the black box to understand its functionality, especially given he had signed an NDA and was being considered for a leadership role. Holmes firmly refused, stating, "absolutely not." This lack of transparency, coupled with her vague answers regarding the technology's capabilities beyond simple measures like glucose or sodium, led Attia to decide against joining the company, despite the potential financial windfall.
• The Unraveling and Attia's Validation: Fast forward to 2015, Attia saw Holmes on the cover of Forbes with a company valued at over nine billion dollars. He later encountered her at a Vanity Fair event in San Francisco, just a week before John Carreyrou's investigative article in The Wall Street Journal exposed Theranos's fraud. Attia felt a sense of validation, realizing his initial skepticism was justified and that his decision to walk away saved him from entanglement in a massive scam.
• Impact on Investors and Continued Delusion: The episode touches on the high-profile individuals and entities duped by Theranos, including Betsy DeVos and General Mattis, who invested significant amounts. Attia shared a conversation with his friend, whose father-in-law—the Stanford professor—was still in the "believing camp" even after the scandal broke, highlighting the deep-seated nature of the deception and the difficulty some had in accepting the truth.

Notable Moments

• Interesting Story/Anecdote: Attia's account of his lunch with Elizabeth Holmes where he was shown the "black box" but denied access to its interior is a crucial moment. His expert questions about chemical assays and Holmes's steadfast refusal to open the device underscore the early signs of deception that he recognized.
• Surprising Fact/Revelation: Attia mentions that at their later encounter at the Vanity Fair event, Holmes not only remembered him but recalled his name and the exact circumstances of their introduction years prior. This suggests a sharp memory, even amidst the impending collapse of her company, and contrasts with the widely known detail about her fake voice.
• Memorable Exchange: A poignant moment is Attia's discussion with his friend after the scandal broke, inquiring about dinner conversations given his friend's father-in-law was still a Theranos believer. This exchange highlights the lingering effects of the deception and the difficulty for some close to the situation to accept the reality of the fraud, even after public exposure.

Key Takeaways

Listeners gain insight into the critical importance of due diligence and transparency, particularly in high-stakes technological ventures. The episode underscores how even highly credentialed individuals can be swayed by charismatic founders and ambitious narratives if fundamental questions about technical feasibility are not rigorously pursued. Attia's experience serves as a cautionary tale, emphasizing the value of trusting one's professional skepticism and the dangers of investing in black-box solutions that lack scientific substantiation. It highlights that true innovation requires open inquiry, not just compelling storytelling.